ROZA VAKSENGISER: Open Payments
NPI 1881993400 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$765 in 26 payments from 13 companies in 2025. Trend: 2023 $586 · 2024 $1,142 · 2025 $765
Food & beverage: $565Education: $200
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. | 6 | $177 |
| SEAGEN INC. | 1 | $100 |
| ABBVIE INC. | 1 | $100 |
| Janssen Biotech, Inc. | 3 | $82 |
| Novartis Pharmaceuticals Corporation | 4 | $68 |
| Celgene Corporation | 2 | $54 |
| Astellas Pharma US Inc | 2 | $46 |
| Pharmacosmos Therapeutics Inc. | 2 | $28 |
| Acrotech Biopharma Inc. | 1 | $28 |
| Gilead Sciences, Inc. | 1 | $27 |
Products named: INJECTAFER, VENCLEXTA, DARZALEX, LEQVIO, REBLOZYL, Vyloy, MONOFERRIC, BELEODAQ.
Industry payments across NY — which companies pay providers there.
